(Bloomberg) — A frenzy around obesity drugs made Novo Nordisk A/S Europe’s biggest stock-market success story of 2023. Repeating the trick won’t be so easy. Most Read from Bloomberg Shares of Novo, which makes the diabetes drug Ozempic and weight loss medicine Wegovy, have risen 42% this year, as investors latched on to the growth […]